CSTL vs. HRMY
Compare and contrast key facts about Castle Biosciences, Inc. (CSTL) and Harmony Biosciences Holdings, Inc. (HRMY).
Performance
CSTL vs. HRMY - Performance Comparison
Loading graphics...
CSTL vs. HRMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
CSTL Castle Biosciences, Inc. | -36.89% | 45.97% | 23.49% | -8.33% | -45.09% | -36.16% | 46.65% |
HRMY Harmony Biosciences Holdings, Inc. | -25.15% | 8.75% | 6.53% | -41.38% | 29.22% | 17.95% | -2.32% |
Fundamentals
CSTL:
$720.13M
HRMY:
$1.64B
CSTL:
-$0.82
HRMY:
$3.33
CSTL:
2.09
HRMY:
1.89
CSTL:
1.53
HRMY:
1.89
CSTL:
$344.23M
HRMY:
$868.45M
CSTL:
$204.51M
HRMY:
$670.11M
CSTL:
$8.22M
HRMY:
$238.25M
Returns By Period
In the year-to-date period, CSTL achieves a -36.89% return, which is significantly lower than HRMY's -25.15% return.
CSTL
- 1D
- 4.25%
- 1M
- -16.98%
- YTD
- -36.89%
- 6M
- 7.82%
- 1Y
- 22.63%
- 3Y*
- 2.62%
- 5Y*
- -19.15%
- 10Y*
- —
HRMY
- 1D
- 4.13%
- 1M
- -1.86%
- YTD
- -25.15%
- 6M
- 1.63%
- 1Y
- -15.61%
- 3Y*
- -4.98%
- 5Y*
- -2.68%
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CSTL vs. HRMY — Risk / Return Rank
CSTL
HRMY
CSTL vs. HRMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Castle Biosciences, Inc. (CSTL) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CSTL | HRMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.38 | -0.37 | +0.75 |
Sortino ratioReturn per unit of downside risk | 1.09 | -0.24 | +1.33 |
Omega ratioGain probability vs. loss probability | 1.13 | 0.96 | +0.17 |
Calmar ratioReturn relative to maximum drawdown | 0.51 | -0.45 | +0.96 |
Martin ratioReturn relative to average drawdown | 1.30 | -0.98 | +2.28 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| CSTL | HRMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.38 | -0.37 | +0.75 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.26 | -0.05 | -0.21 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.03 | -0.09 | +0.12 |
Correlation
The correlation between CSTL and HRMY is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
CSTL vs. HRMY - Dividend Comparison
Neither CSTL nor HRMY has paid dividends to shareholders.
Drawdowns
CSTL vs. HRMY - Drawdown Comparison
The maximum CSTL drawdown since its inception was -88.02%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for CSTL and HRMY.
Loading graphics...
Drawdown Indicators
| CSTL | HRMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -88.02% | -68.48% | -19.54% |
Max Drawdown (1Y)Largest decline over 1 year | -45.33% | -34.49% | -10.84% |
Max Drawdown (5Y)Largest decline over 5 years | -84.97% | -68.48% | -16.49% |
Current DrawdownCurrent decline from peak | -74.78% | -54.01% | -20.77% |
Average DrawdownAverage peak-to-trough decline | -54.08% | -34.74% | -19.34% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.78% | 15.95% | +1.83% |
Volatility
CSTL vs. HRMY - Volatility Comparison
Castle Biosciences, Inc. (CSTL) has a higher volatility of 9.82% compared to Harmony Biosciences Holdings, Inc. (HRMY) at 8.18%. This indicates that CSTL's price experiences larger fluctuations and is considered to be riskier than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| CSTL | HRMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.82% | 8.18% | +1.64% |
Volatility (6M)Calculated over the trailing 6-month period | 36.73% | 31.02% | +5.71% |
Volatility (1Y)Calculated over the trailing 1-year period | 59.76% | 41.98% | +17.78% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 73.92% | 50.63% | +23.29% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 74.42% | 52.83% | +21.59% |
Financials
CSTL vs. HRMY - Financials Comparison
This section allows you to compare key financial metrics between Castle Biosciences, Inc. and Harmony Biosciences Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CSTL vs. HRMY - Profitability Comparison
CSTL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Castle Biosciences, Inc. reported a gross profit of 0.00 and revenue of 87.01M. Therefore, the gross margin over that period was 0.0%.
HRMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Harmony Biosciences Holdings, Inc. reported a gross profit of 175.23M and revenue of 243.78M. Therefore, the gross margin over that period was 71.9%.
CSTL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Castle Biosciences, Inc. reported an operating income of -3.83M and revenue of 87.01M, resulting in an operating margin of -4.4%.
HRMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Harmony Biosciences Holdings, Inc. reported an operating income of 38.56M and revenue of 243.78M, resulting in an operating margin of 15.8%.
CSTL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Castle Biosciences, Inc. reported a net income of -2.33M and revenue of 87.01M, resulting in a net margin of -2.7%.
HRMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Harmony Biosciences Holdings, Inc. reported a net income of 59.03M and revenue of 243.78M, resulting in a net margin of 24.2%.